(FM) Inmunología
Departamento académico
María Esperanza
Rodríguez Ruiz
Consultora Médica
Publicaciones en las que colabora con María Esperanza Rodríguez Ruiz (55)
2024
-
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials
Nature Communications, Vol. 15, Núm. 1
-
Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-priming
Immunological Reviews, Vol. 321, Núm. 1, pp. 143-151
-
Low-Dose Ionizing γ-Radiation Elicits the Extrusion of Neutrophil Extracellular Traps
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 18, pp. 4131-4142
-
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors
Clinical Cancer Research, Vol. 30, Núm. 13, pp. 2693-2701
2023
-
Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control
Journal for immunotherapy of cancer, Vol. 11, Núm. 1
-
Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic
OncoImmunology, Vol. 12, Núm. 1
2022
-
Charting roadmaps towards novel and safe synergistic immunotherapy combinations
Nature Cancer, Vol. 3, Núm. 6, pp. 665-680
-
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
Cancer Discovery, Vol. 12, Núm. 5, pp. 1248-1265
-
Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
Journal for immunotherapy of cancer, Vol. 10, Núm. 3
-
Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers
Theranostics, Vol. 12, Núm. 3, pp. 1373-1387
-
Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer
Cancer Discovery, Vol. 12, Núm. 5, pp. 1356-1377
2021
-
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic
Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, Núm. 26
-
CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation
Nature Communications, Vol. 12, Núm. 1
-
Consolidating radiotherapy with immunotherapy
Clinical Cancer Research, Vol. 27, Núm. 20
-
Differential Interleukin-8 thresholds for chemotaxis and netosis in human neutrophils
European Journal of Immunology, Vol. 51, Núm. 9, pp. 2274-2280
-
Heterogenous presence of neutrophil extracellular traps in human solid tumours is partially dependent on IL-8
Journal of Pathology, Vol. 255, Núm. 2, pp. 190-201
-
Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 11
-
Paradigms on immunotherapy combinations with chemotherapy
Cancer Discovery, Vol. 11, Núm. 6, pp. 1353-1367
2020
-
CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity
Immunity, Vol. 52, Núm. 5, pp. 856-871.e8
-
Cellular cytotoxicity is a form of immunogenic cell death
Journal for ImmunoTherapy of Cancer, Vol. 8, Núm. 1